Global Gastroparesis Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Idiopathic, Diabetic, Post-Surgical, and Others.By Drug Class;
Prokinetic Drugs, Antiemetics, Antidepressants, and Others.By End User;
Hospitals and Surgical Centers, Ambulatory Care Centers, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Gastroparesis Treatment Market (USD Million), 2021 - 2031
In the year 2024, the Global Gastroparesis Treatment Market was valued at USD 5,464.88 million. The size of this market is expected to increase to USD 7,000.02 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.6%.
The global gastroparesis treatment market encompasses a diverse range of therapeutic interventions aimed at managing the symptoms and underlying causes of gastroparesis, a chronic digestive disorder characterized by delayed stomach emptying. This condition can lead to a variety of debilitating symptoms such as nausea, vomiting, abdominal pain, bloating, and early satiety, significantly impacting patients' quality of life. The market is driven by the increasing prevalence of gastroparesis, rising awareness among healthcare professionals and patients, and advancements in treatment modalities.
One of the key drivers of the global gastroparesis treatment market is the growing prevalence of gastroparesis worldwide, attributed to factors such as the rising incidence of diabetes, a leading cause of secondary gastroparesis, and changes in lifestyle and dietary habits. As the prevalence of risk factors associated with gastroparesis continues to rise, there is a corresponding increase in the number of patients seeking medical intervention for symptom management and disease progression. This trend has led to heightened interest and investment in the development of novel therapeutics and treatment approaches tailored to the diverse needs of gastroparesis patients.
Advancements in treatment modalities are shaping the landscape of the global gastroparesis treatment market, offering patients a variety of options to alleviate symptoms and improve gastric motility. Pharmacological interventions such as prokinetic agents, antiemetics, and symptom-relieving medications form the cornerstone of gastroparesis management, providing relief from nausea, vomiting, and other gastrointestinal symptoms. In addition to pharmacotherapy, non-pharmacological approaches such as dietary modifications, lifestyle changes, enteral nutrition, and gastric electrical stimulation (GES) therapy are increasingly utilized to address the multifactorial nature of gastroparesis and optimize patient outcomes. Moreover, ongoing research efforts focused on understanding the pathophysiology of gastroparesis and identifying novel therapeutic targets hold promise for further advancing treatment options and enhancing the standard of care for patients worldwide.
Global Gastroparesis Treatment Market Recent Developments
-
In December 2023, Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. This strategy is expected to spur company’s product pipeline and offerings.
-
In June 2020, Evoke Pharma, Inc. a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. This strategy enabled company to add value to its existing product portfolio.
Segment Analysis
The Global Gastroparesis Treatment Market has been segmented by Type, Drug Class, End User and Geography, type into pharmacological treatments, surgical interventions, and medical devices. Pharmacological treatments dominate the market and include prokinetic agents like metoclopramide and domperidone, which help stimulate gastric motility. Antiemetic drugs, such as ondansetron, are also used to manage nausea and vomiting associated with gastroparesis. Surgical interventions, including gastric electrical stimulation (GES) and pyloroplasty, are employed in severe cases where medications do not provide sufficient relief. Additionally, medical devices like feeding tubes may be used in patients with significant malnutrition or when oral intake is not feasible due to the condition.
The market is also segmented by drug class, with prokinetic agents and antiemetics being the primary drug classes used in the treatment of gastroparesis. Prokinetic agents work by enhancing gastric motility, improving the emptying of the stomach, and alleviating symptoms such as nausea, bloating, and discomfort. Antiemetics help to reduce nausea and vomiting, which are common symptoms of the condition. Other treatments in the market include analgesics and dietary supplements that assist in managing pain and improving nutritional status. These drug classes are commonly prescribed based on the severity of the condition and the specific symptoms exhibited by the patient.
End users of gastroparesis treatments include hospitals, outpatient clinics, and home care settings. Hospitals are the primary end users, especially for surgical interventions, gastric electrical stimulation, and specialized medical care for severe cases. Outpatient clinics also play a significant role in managing milder cases of gastroparesis, with patients typically receiving medication and dietary modifications. Geographically, North America leads the market, driven by advanced healthcare systems, a high prevalence of diabetes (a key risk factor for gastroparesis), and access to the latest treatment options. Europe follows, with a strong healthcare infrastructure and increasing awareness about the condition. The Asia-Pacific region is experiencing rapid growth, driven by expanding healthcare access, rising incidence of gastrointestinal disorders, and growing awareness of gastroparesis as a significant health issue.
Global Gastroparesis Treatment Segment Analysis
In this report, the Global Gastroparesis Treatment Market has been segmented by Type, Drug Class, End User and Geography.
Global Gastroparesis Treatment Market, Segmentation by Type
The Global Gastroparesis Treatment Market has been segmented by Type into Idiopathic, Diabetic, Post-Surgical, and Others.
Idiopathic gastroparesis represents a significant segment of the gastroparesis treatment market, accounting for a substantial proportion of cases where the underlying cause of delayed gastric emptying is unknown. Idiopathic gastroparesis often presents with nonspecific symptoms such as nausea, vomiting, abdominal pain, and bloating, making diagnosis challenging and requiring comprehensive evaluation to rule out other potential causes. Treatment strategies for idiopathic gastroparesis focus on symptom management and optimizing gastric motility through a combination of pharmacological interventions, dietary modifications, and non-pharmacological therapies tailored to individual patient needs.
Diabetic gastroparesis constitutes another prominent segment of the gastroparesis treatment market, characterized by delayed gastric emptying secondary to autonomic neuropathy in patients with diabetes mellitus. Diabetic gastroparesis is associated with poorly controlled blood glucose levels, prolonged disease duration, and microvascular complications, contributing to the pathogenesis and progression of gastroparesis symptoms. Treatment of diabetic gastroparesis involves optimizing glycemic control, managing diabetic complications, and addressing gastrointestinal symptoms using prokinetic agents, antiemetics, dietary modifications, and other supportive measures. Multidisciplinary collaboration between endocrinologists, gastroenterologists, and dietitians is essential for achieving optimal outcomes in patients with diabetic gastroparesis.
Post-surgical gastroparesis represents a distinct segment of the gastroparesis treatment market, occurring as a complication of upper gastrointestinal (GI) surgeries such as fundoplication, gastric bypass, or esophagectomy. Post-surgical gastroparesis may result from vagal nerve injury, disruption of gastric motility mechanisms, or anatomical changes affecting gastric emptying dynamics. Management of post-surgical gastroparesis involves addressing underlying surgical complications, optimizing nutritional support, and implementing pharmacological and non-pharmacological interventions to alleviate symptoms and restore normal gastric function. Close monitoring and collaboration between surgeons, gastroenterologists, and nutrition specialists are essential for identifying and managing post-surgical gastroparesis effectively.
Global Gastroparesis Treatment Market, Segmentation by Drug Class
The Global Gastroparesis Treatment Market has been segmented by Drug Class into Prokinetic Drugs, Antiemetics, Antidepressants, and Others.
Prokinetic drugs represent a fundamental segment of the gastroparesis treatment market, encompassing medications that enhance gastrointestinal motility and facilitate gastric emptying. Prokinetic agents such as metoclopramide, domperidone, and erythromycin act on receptors within the gastrointestinal tract to stimulate smooth muscle contractions and accelerate transit through the digestive system. These medications are commonly prescribed to alleviate symptoms of gastroparesis such as nausea, vomiting, and early satiety, improving overall gastric function and enhancing patient quality of life. Understanding the role of prokinetic drugs in gastroparesis management enables healthcare providers to tailor treatment regimens to individual patient needs and preferences, considering factors such as medication efficacy, tolerability, and potential side effects.
Antiemetics constitute another important segment of the gastroparesis treatment market, comprising medications used to control nausea and vomiting, which are common symptoms of gastroparesis. Antiemetic agents such as ondansetron, promethazine, and prochlorperazine work by blocking serotonin receptors in the central nervous system and gastrointestinal tract, inhibiting the emetic reflex and reducing the sensation of nausea. Antiemetics may be prescribed as adjunctive therapy alongside prokinetic drugs or as standalone agents for managing gastroparesis symptoms, particularly in patients with refractory nausea and vomiting. By incorporating antiemetics into treatment regimens, healthcare providers can effectively alleviate gastrointestinal symptoms and improve patient comfort and well-being.
Antidepressants represent a unique segment of the gastroparesis treatment market, reflecting the role of psychological factors in modulating gastrointestinal function and symptom perception. Tricyclic antidepressants (TCAs) such as amitriptyline and nortriptyline are commonly used off-label to manage symptoms of gastroparesis, including abdominal pain, bloating, and early satiety. TCAs exert their effects by modulating neurotransmitter levels in the central nervous system, enhancing pain modulation, and reducing visceral hypersensitivity associated with gastroparesis. Additionally, selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and sertraline may be prescribed to manage comorbid depression or anxiety commonly observed in gastroparesis patients. By addressing both physical and psychological aspects of gastroparesis, antidepressants play a valuable role in comprehensive symptom management and improving patient quality of life.
Global Gastroparesis Treatment Market, Segmentation by End User
The Global Gastroparesis Treatment Market has been segmented by End User into Hospitals and Surgical Centers, Ambulatory Care Centers and Others.
The global gastroparesis treatment market is segmented by end user into hospitals and surgical centers, ambulatory care centers, and others. Hospitals and surgical centers are the largest end users of gastroparesis treatments, as they are equipped to handle severe and complicated cases. Hospitals offer comprehensive care for patients with advanced gastroparesis, providing diagnostic services, medical management, and surgical interventions when necessary, such as gastric pacemaker implantation or surgical treatments for refractory cases. Surgical centers also specialize in performing procedures that can help manage symptoms or complications associated with gastroparesis, including gastrectomies or placement of feeding tubes.
Ambulatory care centers are an increasingly important segment in the gastroparesis treatment market. These centers focus on outpatient care, offering ongoing management for less severe or stable cases of gastroparesis. Treatments at ambulatory care centers include medication management, dietary modifications, and less invasive therapies like enteral feeding or percutaneous endoscopic gastrostomy (PEG) tube placements. These centers provide a more cost-effective environment for patients who do not require hospitalization but need regular monitoring and treatment to control their condition. The convenience and lower cost of ambulatory care centers contribute to their growing role in managing gastroparesis.
The "others" category includes specialized clinics, primary care providers, and home healthcare settings. Specialized clinics, particularly those focusing on gastrointestinal disorders, play a critical role in the diagnosis and management of gastroparesis, offering advanced treatments such as Botox injections or electrical stimulation therapy. Primary care providers are often the first point of contact for patients with mild symptoms, managing less complex cases or referring them to specialists. Home healthcare services are also relevant for long-term management, providing patients with personalized care at home, such as nutrition counseling or remote monitoring. Geographically, North America and Europe dominate the gastroparesis treatment market due to their advanced healthcare systems and increasing awareness of the condition. However, the Asia-Pacific region is seeing growth, driven by improving healthcare access and rising rates of gastroparesis in certain populations.
Global Gastroparesis Treatment Market, Segmentation by Geography
In this report, the Global Gastroparesis Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Gastroparesis Treatment Market Share (%), by Geographical Region, 2024
North America, comprising the United States and Canada, is expected to maintain a significant share of the gastroparesis treatment market throughout the forecast period. The region benefits from advanced healthcare systems, high awareness levels among healthcare professionals and patients, and robust research infrastructure, driving innovation and advancements in gastroparesis management. Increasing prevalence of risk factors such as diabetes and gastrointestinal disorders, coupled with rising healthcare expenditures and expanding treatment options, contribute to market growth in North America. Additionally, strategic collaborations between industry stakeholders, academic institutions, and patient advocacy groups foster research and development initiatives, accelerating progress in gastroparesis treatment and improving patient outcomes.
Europe represents another key market for gastroparesis treatment, comprising countries such as the United Kingdom, Germany, France, and Italy. European healthcare systems prioritize comprehensive care delivery, emphasizing early diagnosis, multidisciplinary treatment approaches, and patient-centered care. Rising prevalence of gastroparesis risk factors such as diabetes and neurologic disorders, coupled with increasing awareness and adoption of advanced treatment modalities, contribute to market expansion in Europe. Furthermore, regulatory initiatives aimed at standardizing treatment guidelines, enhancing patient access to innovative therapies, and promoting research collaborations drive advancements in gastroparesis management across the region.
The Asia Pacific region, including countries such as China, Japan, India, and Australia, presents significant growth opportunities for the gastroparesis treatment market during the forecast period. Rapid urbanization, changing dietary habits, and increasing prevalence of diabetes and gastrointestinal disorders contribute to the rising burden of gastroparesis in Asia Pacific. However, challenges such as limited healthcare infrastructure, disparities in access to specialized care, and cultural differences in disease perception and management may impede market growth in certain regions. Nonetheless, increasing investments in healthcare infrastructure, efforts to raise disease awareness, and collaborations between international and local stakeholders drive progress in gastroparesis treatment and improve patient outcomes throughout Asia Pacific.
The Middle East and Africa region, comprising countries in the Gulf Cooperation Council (GCC) countries, South Africa, and others, represents an emerging market for gastroparesis treatment. While the prevalence of gastroparesis in this region may be lower compared to other parts of the world, increasing adoption of Western dietary patterns, rising prevalence of diabetes and gastrointestinal disorders, and improving access to healthcare services contribute to market growth in the Middle East and Africa. Moreover, strategic partnerships between healthcare providers, government agencies, and industry stakeholders drive initiatives to enhance disease awareness, improve diagnostic capabilities, and expand treatment options for gastroparesis patients across the region.
Latin America, including countries such as Brazil, Mexico, and Argentina, presents another emerging market for gastroparesis treatment. Increasing urbanization, changing lifestyles, and rising prevalence of diabetes and gastrointestinal disorders contribute to the growing burden of gastroparesis in Latin America. Efforts to strengthen healthcare infrastructure, promote disease awareness, and enhance patient access to innovative therapies drive market growth in the region. Additionally, collaborations between public and private sectors, along with initiatives to harmonize regulatory frameworks and improve healthcare delivery, foster advancements in gastroparesis treatment and improve patient outcomes throughout Latin America.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Gastroparesis Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Prevalence of Diabetes
- Growing Demand for Minimally Invasive Procedures
- Expanding Pipeline of Novel Therapies
-
Rising Awareness among Healthcare Professionals - The rising awareness among healthcare professionals about gastroparesis is pivotal in improving patient outcomes and advancing the treatment landscape for this condition. As healthcare providers gain a deeper understanding of the pathophysiology, clinical manifestations, and diagnostic approaches to gastroparesis, they are better equipped to recognize and diagnose the condition in a timely manner. Increased awareness also enables healthcare professionals to differentiate gastroparesis from other gastrointestinal disorders with similar symptoms, facilitating more accurate diagnosis and personalized treatment strategies.
Heightened awareness among healthcare professionals fosters interdisciplinary collaboration and knowledge-sharing across different specialties, including gastroenterology, endocrinology, and primary care. This interdisciplinary approach to care allows for comprehensive evaluation and management of gastroparesis, addressing not only the gastrointestinal symptoms but also the underlying etiology, comorbidities, and psychosocial factors that may impact patient outcomes. Additionally, increased awareness prompts healthcare professionals to stay abreast of the latest research findings, treatment guidelines, and emerging therapies for gastroparesis, ensuring that patients receive evidence-based and up-to-date care.
Rising awareness among healthcare professionals can lead to improved patient education and support initiatives, as providers are better able to educate patients about their condition, treatment options, and self-management strategies. By fostering open communication and collaboration between healthcare providers and patients, awareness initiatives empower individuals with gastroparesis to actively participate in their care, make informed decisions, and advocate for their needs. Additionally, increased awareness may facilitate the development of specialized clinics, multidisciplinary care teams, and dedicated resources for patients with gastroparesis, enhancing the quality and accessibility of care for this patient population.
Restraints
- High Cost of Neurostimulation Devices
- Challenges in Diagnosis and Patient Management
- Adverse Effects Associated with Treatment
-
Stringent Regulatory Approval Process - The stringent regulatory approval process presents a significant challenge in bringing new treatments for gastroparesis to market. Regulatory agencies such as the FDA and EMA require extensive preclinical and clinical data to demonstrate the safety, efficacy, and quality of investigational drugs and medical devices before they can be approved for commercialization. This process involves rigorous review and evaluation of clinical trial results, manufacturing practices, and risk-benefit profiles to ensure that approved treatments meet the highest standards of safety and effectiveness.
Navigating the regulatory approval process for gastroparesis treatments can be time-consuming, complex, and resource-intensive for pharmaceutical companies and device manufacturers. It often requires conducting large-scale clinical trials with well-defined endpoints and patient populations, adhering to Good Clinical Practice (GCP) guidelines, and addressing any regulatory concerns or requests for additional data or analyses. Furthermore, the regulatory requirements may vary depending on the geographic region, with differences in submission timelines, data requirements, and post-market surveillance obligations adding to the complexity of the process.
Despite these challenges, overcoming the stringent regulatory approval process is essential for ensuring the safety and efficacy of gastroparesis treatments and gaining market access for innovative therapies. Pharmaceutical companies and device manufacturers must work closely with regulatory agencies, clinical experts, and other stakeholders to develop comprehensive regulatory strategies, streamline the approval process, and address any regulatory hurdles or uncertainties proactively. Additionally, leveraging expedited pathways such as Fast Track designation, Breakthrough Therapy designation, or Orphan Drug designation can help accelerate the development and approval of promising treatments for gastroparesis, particularly for patients with unmet medical needs.
Opportunities
- Expansion into Emerging Markets
- Integration of Digital Health Solutions
- Collaboration for Clinical Trials
-
Patient Education and Support Programs - Patient education and support programs are essential components of comprehensive care for individuals living with gastroparesis. These initiatives aim to empower patients with knowledge about their condition, treatment options, and self-management strategies, enabling them to actively participate in their care and improve their quality of life. By providing accurate and accessible information, healthcare providers can help patients better understand the underlying causes of gastroparesis, common symptoms, and potential complications, fostering a sense of control and agency over their health.
Patient education and support programs play a crucial role in promoting adherence to treatment regimens and self-care practices. By providing guidance on dietary modifications, medication management, symptom monitoring, and coping strategies, these programs empower patients to proactively manage their symptoms and minimize the impact of gastroparesis on their daily lives. Additionally, ongoing education and support can help patients navigate healthcare systems, advocate for their needs, and make informed decisions about their care, fostering a collaborative and patient-centered approach to managing gastroparesis.
In conclusion, patient education and support programs are integral components of holistic care for individuals affected by gastroparesis. By providing education, resources, and emotional support, healthcare providers can empower patients to effectively manage their condition, improve their quality of life, and thrive despite the challenges posed by gastroparesis. Investing in these programs not only benefits individual patients and their families but also contributes to building a more informed, resilient, and supportive gastroparesis community.
Competitive Landscape Analysis
Key players in Global Gastroparesis Treatment Market include :
- Medtronic
- Kimberly-Clark Corporation
- Abbott Laboratories
- Salix Pharmaceuticals
- Boston Scientific Corporation
- Rhythm Pharmaceuticals
- Cardinal Health
- Alfa Wassermann SPA
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Class
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Gastroparesis Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Diabetes
- Growing Demand for Minimally Invasive Procedures
- Expanding Pipeline of Novel Therapies
- Rising Awareness among Healthcare Professionals
- Restraints
- High Cost of Neurostimulation Devices
- Challenges in Diagnosis and Patient Management
- Adverse Effects Associated with Treatment
- Stringent Regulatory Approval Process
- Opportunities
- Expansion into Emerging Markets
- Integration of Digital Health Solutions
- Collaboration for Clinical Trials
- Patient Education and Support Programs
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Gastroparesis Treatment Market, By Type, 2021 - 2031 (USD Million)
- Idiopathic
- Diabetic
- Post-Surgical
- Others
- Global Gastroparesis Treatment Market, By Drug Class, 2021 - 2031 (USD Million)
- Prokinetic Drugs
- Antiemetics
- Antidepressants
- Others
- Global Gastroparesis Treatment Market, By End User, 2021 - 2031 (USD Million)
- Hospitals and Surgical Centers
- Ambulatory Care Centers
- Others
- Global Gastroparesis Treatment Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Gastroparesis Treatment Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Medtronic
- Kimberly-Clark Corporation
- Abbott Laboratories
- Salix Pharmaceuticals
- Boston Scientific Corporation
- Rhythm Pharmaceuticals
- Cardinal Health
- Alfa Wassermann SPA
- Company Profiles
- Analyst Views
- Future Outlook of the Market